Recombinant Anti-EpCAM antibody [VU-1D9] (ab187372)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Mouse monoclonal [VU-1D9] to EpCAM
- Suitable for: Flow Cyt, ICC/IF
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-EpCAM antibody [VU-1D9]
See all EpCAM primary antibodies -
Description
Mouse monoclonal [VU-1D9] to EpCAM -
Host species
Mouse -
Tested applications
Suitable for: Flow Cyt, ICC/IFmore details -
Species reactivity
Reacts with: Human -
Immunogen
Tissue, cells or virus corresponding to Human EpCAM.
Database link: P16422 -
Positive control
- Flow Cyt: HT-29 cells. ICC/IF: HT-29, T47D and A431 cells.
-
General notes
This product was switched from a hybridoma to a recombinant production format on 26th October 2021.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 0.05% BSA, 40% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
VU-1D9 -
Isotype
IgG1 -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
KO cell lines
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab187372 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
1/1000.
|
|
ICC/IF |
1/250.
|
Notes |
---|
Flow Cyt
1/1000. |
ICC/IF
1/250. |
Target
-
Function
May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E. -
Tissue specificity
Highly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma. -
Involvement in disease
Defects in EPCAM are the cause of diarrhea type 5 (DIAR5) [MIM:613217]. It is an intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum.
Defects in EPCAM are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM. -
Sequence similarities
Belongs to the EPCAM family.
Contains 1 thyroglobulin type-1 domain. -
Post-translational
modificationsHyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability. -
Cellular localization
Lateral cell membrane. Cell junction > tight junction. Co-localizes with CLDN7 at the lateral cell membrane and tight junction. - Information by UniProt
-
Database links
- Entrez Gene: 4072 Human
- Omim: 185535 Human
- SwissProt: P16422 Human
- Unigene: 542050 Human
-
Alternative names
- 17 1A antibody
- 323/A3 antibody
- Adenocarcinoma associated antigen antibody
see all
Images
-
Flow cytometric analysis of Jurkat (Human T cell leukemia T lymphocyte, Left) / HT-29 (Human colorectal adenocarcinoma epithelial cell, Right) labeling EpCAM with ab187372 at 1/1000 dilution, followed by secondary antibody ab150113 (Goat anti mouse IgG (Alexa Fluor® 488)) at 1/2000 dilution (Red). Compared with a Mouse monoclonal IgG isotype control (Black) and an unlabelled control (Cell without incubation with primary antibody and secondary antibody) (Blue). Gated on viable cells.
Negative control: Jurkat (PMID: 29352248)
-
ab187372 staining EpCAM in HT-29 cell line (top panel) and Jurkat negative cells (bottom panel). The cells were fixed with 4% paraformaldehyde then permeabilized with 0.1% TritonX-100. The cells were then incubated with ab187372 at 1/250 concentration and counterstained with ab179513 (Anti-beta Tubulin rabbit monoclonal antibody) at 1/200 dilution, followed by secondary antibody ab150113 (Goat Anti-Mouse IgG H&L (Alexa Fluor® 488)) at 1/1000 dilution (shown in green) and counterstained with ab150080 (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594)) at 1/500 dilution (shown in red). Nuclear DNA was labelled in blue with DAPI.
Confocal image showing membranous staining in HT-29 cell line.
Negative control: Jurkat (PMID: 29352248) -
ab187372 staining EpCAM in wild-type A431 cells (top panel) and EpCAM knockout A431 cells (bottom panel). The cells were fixed with 100% methanol (5 min) then permeabilized with 0.1% PBS-Tween for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated with ab187372 at 0.5μg/ml concentration and ab6046 (Rabbit polyclonal to beta Tubulin) at 1/1000 dilution overnight at 4°C followed by a further incubation at room temperature for 1h with a goat secondary antibody to mouse IgG (Alexa Fluor® 488) (ab150117) at 2 μg/ml (shown in green) and a goat secondary antibody to rabbit IgG (Alexa Fluor® 594) (ab150080) at 2 μg/ml (shown in red). Nuclear DNA was labelled in blue with DAPI.
Image was taken with a confocal microscope (Leica-Microsystems TCS SP8). -
ab187372 staining EpCAM in T47D positive cells (top panel) and HeLa negative cells (bottom panel). The cells were fixed with 4% paraformaldehyde (10 min) then permeabilized with 0.1% PBS-Tween for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated with ab187372 at 1μg/ml concentration and ab6046 (Rabbit polyclonal to beta Tubulin) at 1/1000 dilution overnight at 4°C followed by a further incubation at room temperature for 1h with a goat secondary antibody to mouse IgG (Alexa Fluor® 488) (ab150117) at 2 μg/ml (shown in green) and a goat secondary antibody to rabbit IgG (Alexa Fluor® 594) (ab150080) at 2 μg/ml (shown in red). Nuclear DNA was labelled in blue with DAPI. This antibody performed similarly using 100% methanol fixation. Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a single confocal section is shown.
-
ab187372 staining EpCAM in wild-type A431 cells (top panel) and EpCAM knockout A431 cells (bottom panel). The cells were fixed with 4% paraformaldehyde (10 min) then permeabilized with 0.1% PBS-Tween for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1% PBS-Tween for 1h. The cells were then incubated with ab187372 at 0.1μg/ml concentration and ab6046 (Rabbit polyclonal to beta Tubulin) at 1/1000 dilution overnight at 4°C followed by a further incubation at room temperature for 1h with a goat secondary antibody to mouse IgG (Alexa Fluor® 488) (ab150117) at 2 μg/ml (shown in green) and a goat secondary antibody to rabbit IgG (Alexa Fluor® 594) (ab150080) at 2 μg/ml (shown in red). Nuclear DNA was labelled in blue with DAPI. This antibody performed similarly using 100% methanol fixation. Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a single confocal section is shown.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (5)
ab187372 has been referenced in 5 publications.
- Wang M et al. RhoJ facilitates angiogenesis in glioblastoma via JNK/VEGFR2 mediated activation of PAK and ERK signaling pathways. Int J Biol Sci 18:942-955 (2022). PubMed: 35173528
- Dai Y et al. A Multivariate Diagnostic Model Based on Urinary EpCAM-CD9-Positive Extracellular Vesicles for Prostate Cancer Diagnosis. Front Oncol 11:777684 (2021). PubMed: 34900726
- van den Brand D et al. EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer. Cancers (Basel) 12:N/A (2020). PubMed: 32630661
- Parker SG et al. A photoelectrochemical platform for the capture and release of rare single cells. Nat Commun 9:2288 (2018). PubMed: 29895867
- Bohmer N et al. Removal of Cells from Body Fluids by Magnetic Separation in Batch and Continuous Mode: Influence of Bead Size, Concentration, and Contact Time. ACS Appl Mater Interfaces 9:29571-29579 (2017). PubMed: 28805365